1.2 Million Invested in MS Care and Innovation

Posted November 27, 2013

Novartis Pharmaceuticals Canada Inc. (Novartis) announced today an investment of 1.2 million in Alberta to collaborate with the Alberta government to advance care and innovation in multiple sclerosis (MS). This investment by Novartis, for MS research, marks the first collaboration under a memorandum of understanding (MOU) between Novartis and the Alberta government intended to stimulate health research and innovation in the province of Alberta.

The 1.2-million Novartis investment will support research for the treatment of MS. The goal is to look at novel innovations, evaluation methods and care pathways and to translate these into practice to further the understanding of the disease and care of MS patients.

For more details, see the FULL ARTICLE.